These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

300 related items for PubMed ID: 16271271

  • 1. Modelling the impact of opportunistic screening on the sequelae and public healthcare costs of infection with Chlamydia trachomatis in Australian women.
    Ward B, Rodger AJ, Jackson TJ.
    Public Health; 2006 Jan; 120(1):42-9. PubMed ID: 16271271
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. [Opportunistic screening for genital infections with Chlamydia trachomatis in sexually active population of Amsterdam. II. Cost-effectiveness analysis of screening women].
    Postma MJ, Welte R, van den Hoek JA, van Doornum GJ, Coutinho RA, Jager JC.
    Ned Tijdschr Geneeskd; 1999 Mar 27; 143(13):677-81. PubMed ID: 10321301
    [Abstract] [Full Text] [Related]

  • 4. Cost-effectiveness analysis of screening adolescent males for Chlamydia on admission to detention.
    Blake DR, Gaydos CA, Quinn TC.
    Sex Transm Dis; 2004 Feb 27; 31(2):85-95. PubMed ID: 14743071
    [Abstract] [Full Text] [Related]

  • 5. Prediction of costs, effectiveness, and disease control of a population-based program using home sampling for diagnosis of urogenital Chlamydia trachomatis Infections.
    Andersen B, Gundgaard J, Kretzschmar M, Olsen J, Welte R, Oster-Gaard L.
    Sex Transm Dis; 2006 Jul 27; 33(7):407-15. PubMed ID: 16601656
    [Abstract] [Full Text] [Related]

  • 6. The cost and cost-effectiveness of opportunistic screening for Chlamydia trachomatis in Ireland.
    Gillespie P, O'Neill C, Adams E, Turner K, O'Donovan D, Brugha R, Vaughan D, O'Connell E, Cormican M, Balfe M, Coleman C, Fitzgerald M, Fleming C.
    Sex Transm Infect; 2012 Apr 27; 88(3):222-8. PubMed ID: 22213681
    [Abstract] [Full Text] [Related]

  • 7. The program cost and cost-effectiveness of screening men for Chlamydia to prevent pelvic inflammatory disease in women.
    Gift TL, Gaydos CA, Kent CK, Marrazzo JM, Rietmeijer CA, Schillinger JA, Dunne EF.
    Sex Transm Dis; 2008 Nov 27; 35(11 Suppl):S66-75. PubMed ID: 18830137
    [Abstract] [Full Text] [Related]

  • 8. [Screening for asymptomatic Chlamydia trachomatis infection in pregnancy; cost-effectiveness favorable at a minimum prevalence rate of 3% or more].
    Postma MJ, Bakker A, Welte R, van Bergen JE, van den Hoek JA, de Jong-van den Berg LT, Jager JC.
    Ned Tijdschr Geneeskd; 2000 Dec 02; 144(49):2350-4. PubMed ID: 11129971
    [Abstract] [Full Text] [Related]

  • 9. Estimation of the burden of disease and costs of genital Chlamydia trachomatis infection in Canada.
    Tuite AR, Jayaraman GC, Allen VG, Fisman DN.
    Sex Transm Dis; 2012 Apr 02; 39(4):260-7. PubMed ID: 22421691
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Managing genital chlamydia trachomatis infection in Scotland: targeted opportunistic testing or a screening programme?
    Clutterbuck DJ.
    Health Bull (Edinb); 2001 Nov 02; 59(6):396-404. PubMed ID: 12661390
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Modelling the healthcare costs of an opportunistic chlamydia screening programme.
    Adams EJ, LaMontagne DS, Johnston AR, Pimenta JM, Fenton KA, Edmunds WJ.
    Sex Transm Infect; 2004 Oct 02; 80(5):363-70. PubMed ID: 15459403
    [Abstract] [Full Text] [Related]

  • 14. Food for thought in women's health. The gynecologist: the new European gatekeeper in Chlamydia trachomatis infection.
    Polyzos NP, Vittoraki A, Tsappi M, Mauri D, Spiliopoulou A, Tzioras S, Kamposioras K, Ioakeimidou A.
    Acta Obstet Gynecol Scand; 2006 Oct 02; 85(10):1156-9. PubMed ID: 17068672
    [Abstract] [Full Text] [Related]

  • 15. Overestimation of complication rates in evaluations of Chlamydia trachomatis screening programmes--implications for cost-effectiveness analyses.
    van Valkengoed IG, Morré SA, van den Brule AJ, Meijer CJ, Bouter LM, Boeke AJ.
    Int J Epidemiol; 2004 Apr 02; 33(2):416-25. PubMed ID: 15082651
    [Abstract] [Full Text] [Related]

  • 16. [Opportunistic screening for genital infections with Chlamydia trachomatis among the sexually active population in Amsterdam. III. Cost-effectiveness analysis of screening women and the role of reinfection and partner treatment].
    Postma MJ, Welte R, van den Hoek JA, Jager JC, van Doornum GJ, Coutinho RA.
    Ned Tijdschr Geneeskd; 1999 Nov 20; 143(47):2383-5. PubMed ID: 10590778
    [Abstract] [Full Text] [Related]

  • 17. An audit of Chlamydia trachomatis screening in colposcopy--Hartlepool experience.
    Tayal SC, Robertson A, Doxford L.
    Int J STD AIDS; 2005 Jul 20; 16(7):500-1. PubMed ID: 16004631
    [Abstract] [Full Text] [Related]

  • 18. Prevalence of urogenital Chlamydia trachomatis increases significantly with level of urbanisation and suggests targeted screening approaches: results from the first national population based study in the Netherlands.
    van Bergen J, Götz HM, Richardus JH, Hoebe CJ, Broer J, Coenen AJ, PILOT CT study group.
    Sex Transm Infect; 2005 Feb 20; 81(1):17-23. PubMed ID: 15681716
    [Abstract] [Full Text] [Related]

  • 19. [Opportunistic screening for genital infections with Chlamydia trachomatis in sexually active population of Amsterdam. II. Cost-effectiveness analysis of screening women].
    Ruitenberg EN.
    Ned Tijdschr Geneeskd; 1999 May 08; 143(19):1012. PubMed ID: 10368724
    [No Abstract] [Full Text] [Related]

  • 20. Chlamydia trachomatis detection in cervical PreservCyt specimens from an Irish urban female population.
    Keegan H, Ryan F, Malkin A, Griffin M, Lambkin H.
    Cytopathology; 2009 Apr 08; 20(2):111-6. PubMed ID: 18093220
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.